Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $1.07 in the prior trading day, Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) closed at $1.03, down -3.74%. In other words, the price has decreased by -$3.74 from its previous closing price. On the day, 1.29 million shares were traded. IRWD stock price reached its highest trading level at $1.11 during the session, while it also had its lowest trading level at $1.03.
Ratios:
Our goal is to gain a better understanding of IRWD by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.80 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.59. For the most recent quarter (mrq), Quick Ratio is recorded 0.82 and its Current Ratio is at 0.82.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 11 ’25 when Gaskins Tammi L sold 1,316 shares for $0.84 per share. The transaction valued at 1,105 led to the insider holds 241,280 shares of the business.
John Minardo sold 7,754 shares of IRWD for $6,513 on Aug 11 ’25. The Chief Legal Officer now owns 400,378 shares after completing the transaction at $0.84 per share. On Aug 11 ’25, another insider, Martini Gregory S., who serves as the Chief Financial Officer of the company, sold 1,265 shares for $0.84 each. As a result, the insider received 1,063 and left with 182,545 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IRWD now has a Market Capitalization of 167307008 and an Enterprise Value of 673124160. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.54. Its current Enterprise Value per Revenue stands at 2.182 whereas that against EBITDA is 7.186.
Stock Price History:
The Beta on a monthly basis for IRWD is 0.30, which has changed by -0.78361344 over the last 52 weeks, in comparison to a change of 0.15005577 over the same period for the S&P500. Over the past 52 weeks, IRWD has reached a high of $5.20, while it has fallen to a 52-week low of $0.53. The 50-Day Moving Average of the stock is 33.31%, while the 200-Day Moving Average is calculated to be -48.29%.
Shares Statistics:
The stock has traded on average 2.16M shares per day over the past 3-months and 1725630 shares per day over the last 10 days, according to various share statistics. A total of 162.43M shares are outstanding, with a floating share count of 156.35M. Insiders hold about 3.74% of the company’s shares, while institutions hold 90.40% stake in the company. Shares short for IRWD as of 1753920000 were 5382745 with a Short Ratio of 2.49, compared to 1751241600 on 7475343. Therefore, it implies a Short% of Shares Outstanding of 5382745 and a Short% of Float of 5.050000000000001.
Earnings Estimates
Ironwood Pharmaceuticals Inc (IRWD) is currently under the scrutiny of 1.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.11, with high estimates of $0.11 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.21 and $0.21 for the fiscal current year, implying an average EPS of $0.21. EPS for the following year is $0.21, with 3.0 analysts recommending between $0.4 and $0.0.
Revenue Estimates
5 analysts predict $74.22M in revenue for the current quarter. It ranges from a high estimate of $83.4M to a low estimate of $68.4M. As of the current estimate, Ironwood Pharmaceuticals Inc’s year-ago sales were $91.59MFor the next quarter, 5 analysts are estimating revenue of $76.4M. There is a high estimate of $84M for the next quarter, whereas the lowest estimate is $70M.
A total of 5 analysts have provided revenue estimates for IRWD’s current fiscal year. The highest revenue estimate was $275.2M, while the lowest revenue estimate was $264M, resulting in an average revenue estimate of $272.3M. In the same quarter a year ago, actual revenue was $351.41MBased on 5 analysts’ estimates, the company’s revenue will be $258.84M in the next fiscal year. The high estimate is $285M and the low estimate is $225.8M.
